Profiling Antibody Status and Vaccine Effectiveness in Post Vaccination With SARS CoV2 in Ain Shams University

Status

UNKNOWN

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04885764

Acronym

ASU-VAC

Enrollment

4000

Registered

2021-05-13

Start date

2021-02-23

Completion date

2021-12-01

Last updated

2021-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Keywords

Egypt, Ain Shams University, Vaccine

Brief summary

This is a prospective intervention study to assess the effectiveness of both the live attenuated and messenger RNA vaccines against SARS-CoV-2 infection

Detailed description

This is a prospective intervention study to assess the short-term effectiveness of the first dose of both the live attenuated and messenger RNA vaccines against SARS-CoV-2 infection by monitoring the antibodies (IgG, IgM and level of neutralizing antibodies) in sera of post-vaccinated persons. The study also will monitor the incidence of SARS-CoV-2 infection among vaccinees just before the first dose administration, 3 weeks after immunization, at the administration of the second dose, 14 days following the second dose and after 3 and 6 months.

Interventions

BIOLOGICALAstrazeneca/Oxford Vaccine

Viral non replicated vector vaccine contains the gene that encodes for the spike protein on the surface of the SARS-CoV-2 virus given Intramuscular injection in 2 doses 3 months apart

BIOLOGICALSinopharm vaccine

Inactivated vaccine given intramuscular injection in 2 doses 3 weeks apart

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

1. Age \> 18 years old 2. Candidate for receiving vaccination according to health care authorties prioritaizaton

Exclusion criteria

1. SARS-CoV-2 recovered cases \<3 months 2. Individuals who are currently infected with Sars-COV-2 and/or with respiratory symptoms with fever.

Design outcomes

Primary

Measure	Time frame	Description
Short-term effectiveness	21 days of the first dose of vaccine	Assess the short-term effectiveness of the first dose of both the live attenuated and messenger RNA vaccines against SARS-CoV-2 infection by monitoring the antibodies (IgG, IgM and level of neutralizing antibodies) in sera of postvaccinated persons three weeks after first dose

Countries

Egypt

Contacts

Primary ContactSamia Girgis, MD

drsamia.girgis@med.asu.edu.eg01223366500

Backup ContactFatma Soliman E Ebeid, MD

dr.fatma_ebeid@yahoo.com01095569596

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026